ALK-Abelló A/S (ALK-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ALK-Abelló A/S (ALK-B) has a cash flow conversion efficiency ratio of 0.112x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr722.00 Million ≈ $112.96 Million USD) by net assets (Dkr6.45 Billion ≈ $1.01 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ALK-Abelló A/S - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how ALK-Abelló A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ALK-B total debt and obligations for a breakdown of total debt and financial obligations.
ALK-Abelló A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ALK-Abelló A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inpost SA
AS:INPST
|
0.237x |
|
The Federal Bank Limited
NSE:FEDERALBNK
|
0.083x |
|
Planet Labs PBC
NYSE:PL
|
0.082x |
|
BYD Electronic (International) Company Limited
F:4BY
|
0.036x |
|
Commercial Metals Company
NYSE:CMC
|
0.047x |
|
Thai Beverage Public Company Limited
F:T6W
|
0.035x |
|
Shenzhen Capchem Tech
SHE:300037
|
0.033x |
|
UGI Corporation
NYSE:UGI
|
0.013x |
Annual Cash Flow Conversion Efficiency for ALK-Abelló A/S (2005–2025)
The table below shows the annual cash flow conversion efficiency of ALK-Abelló A/S from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see ALK-Abelló A/S stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr6.45 Billion ≈ $1.01 Billion |
Dkr1.82 Billion ≈ $284.28 Million |
0.282x | +24.88% |
| 2024-12-31 | Dkr5.37 Billion ≈ $840.64 Million |
Dkr1.21 Billion ≈ $189.78 Million |
0.226x | +50.52% |
| 2023-12-31 | Dkr4.45 Billion ≈ $695.77 Million |
Dkr667.00 Million ≈ $104.36 Million |
0.150x | +43.79% |
| 2022-12-31 | Dkr3.99 Billion ≈ $623.95 Million |
Dkr416.00 Million ≈ $65.09 Million |
0.104x | -22.43% |
| 2021-12-31 | Dkr3.48 Billion ≈ $544.47 Million |
Dkr468.00 Million ≈ $73.22 Million |
0.134x | +40.87% |
| 2020-12-31 | Dkr3.15 Billion ≈ $493.31 Million |
Dkr301.00 Million ≈ $47.09 Million |
0.095x | +129.69% |
| 2019-12-31 | Dkr3.18 Billion ≈ $496.91 Million |
Dkr132.00 Million ≈ $20.65 Million |
0.042x | +239.08% |
| 2018-12-31 | Dkr3.18 Billion ≈ $497.38 Million |
Dkr-95.00 Million ≈ $-14.86 Million |
-0.030x | +74.60% |
| 2017-12-31 | Dkr3.29 Billion ≈ $514.74 Million |
Dkr-387.00 Million ≈ $-60.55 Million |
-0.118x | -183.50% |
| 2016-12-31 | Dkr2.88 Billion ≈ $449.81 Million |
Dkr405.00 Million ≈ $63.37 Million |
0.141x | +107.61% |
| 2015-12-31 | Dkr2.70 Billion ≈ $421.97 Million |
Dkr183.00 Million ≈ $28.63 Million |
0.068x | -50.09% |
| 2014-12-31 | Dkr2.35 Billion ≈ $368.30 Million |
Dkr320.00 Million ≈ $50.07 Million |
0.136x | +109.40% |
| 2013-12-31 | Dkr2.25 Billion ≈ $351.87 Million |
Dkr146.00 Million ≈ $22.84 Million |
0.065x | +62.94% |
| 2012-12-31 | Dkr2.28 Billion ≈ $357.35 Million |
Dkr91.00 Million ≈ $14.24 Million |
0.040x | -79.97% |
| 2011-12-31 | Dkr2.17 Billion ≈ $339.04 Million |
Dkr431.00 Million ≈ $67.43 Million |
0.199x | +46.48% |
| 2010-12-31 | Dkr2.02 Billion ≈ $315.73 Million |
Dkr274.00 Million ≈ $42.87 Million |
0.136x | +0.68% |
| 2009-12-31 | Dkr1.93 Billion ≈ $301.65 Million |
Dkr260.00 Million ≈ $40.68 Million |
0.135x | +32.86% |
| 2008-12-31 | Dkr1.86 Billion ≈ $291.32 Million |
Dkr189.00 Million ≈ $29.57 Million |
0.102x | -40.78% |
| 2007-12-31 | Dkr2.11 Billion ≈ $330.44 Million |
Dkr362.00 Million ≈ $56.64 Million |
0.171x | +498.19% |
| 2006-12-31 | Dkr2.09 Billion ≈ $327.62 Million |
Dkr60.00 Million ≈ $9.39 Million |
0.029x | +1.65% |
| 2005-12-31 | Dkr6.21 Billion ≈ $971.29 Million |
Dkr175.00 Million ≈ $27.38 Million |
0.028x | -- |
About ALK-Abelló A/S
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more